AUTHORS
Elizabeth Florence Krakow, MD,CM, MSc, Jacob Appelbaum, MD/PhD2, Julie R Boiko, MD, PhD, MS3, Laura S Connelly-Smith, MBBCh4, Catherine J Lee, MD, MS5, Dow Dunbar6, Mary Jaenicke7, Elizabeth Frecker8, Nicole Vartanian9, Geoff R Hill, MD10
AFFILIATIONS
1 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Introduction: Relapse represents the major limitation of allogeneic stem cell transplantation (alloSCT). Immune escape from graft-versus-leukemia (GVL) is associated with downregulation of MHC class II and antigen processing, a process reversible following interferon-gamma (IFNγ) exposure. Interleukin-18 (IL-18) is a master cytokine controlling IFNγ secretion but is rapidly inactivated in vivo by IL-18 binding protein (IL-18BP). Decoy-resistant IL-18 (DR-18; ST-067) is resistant to IL-18BP, has prolonged activity in vivo (Zhou T et al, Nature 2020), and prevents relapse after alloSCT in preclinical systems (Minnie S et al, Sci Immunol, 2022). We hypothesized that DR-18 would generate an IFNγ response to enhance MHC II expression and antigen presentation, thereby inducing responses in patients relapsing after alloSCT. We report the first 8 patients treated on the DR. DREAM study (NCT06492707), a phase 1, open-label, dose-finding trial of weekly subcutaneous DR-18 after alloSCT.
Methods: Adults with persistent/recurrent AML or MDS after alloSCT received 4 weekly induction doses, a 2-week holiday, then up to 4 maintenance doses. Starting doses of 30 µg/kg (cohort 1) or 60 µg/kg (cohort 2) were assigned in cohorts of n = 1 per BOIN algorithm, with subsequent intra-patient dose escalation/de-escalation. Toxicity used CTCAE v5.0; response used ELN criteria. Cytokine analysis and single-cell RNA sequencing were performed.
Results: As of 06-2026, 8 patients with adverse AML/MDS genetic risk were treated (6 cohort 1, 2 cohort 2; median age 60 [27-76]; 4 female; 7 White, 1 Asian). They had received a median 3.5 (range 2-7) prior lines of treatment. Pre-DR-18, malignant blasts ranged from 0.03% to 46%. Following DR-18, cytokine release syndrome (CRS) occurred in 6 patients (grade 1 n= 5 events/4 patients; grade 2 n=4 events/1 patient; grade 3 n=1) at doses of 15 to 90 µg/kg. Two patients/3 CRS events required tocilizumab/dexamethasone. One patient with grade 3 CRS after dose #3 (60 µg/kg) required inotrope support with concurrent development of hemophagocytic lymphohistiocytosis (HLH) manifesting as cytopenias, marrow hypoplasia with hemophagocytosis, acute kidney injury, and markedly elevated ferritin (437,532 ng/mL), sIL-2R (19999 pg/mL) and CXCL9 (233,000 pg/ml, normal < 121). She was additionally treated with anakinra and ruxolitinib with complete resolution over 18 days. LFT elevations were mostly mild (max grade 1 n = 2 patients; grade 2 n=3; grade 3 n=1). No patients developed ICANS or confirmed GVHD. There were 2 dose limiting toxicities, grade 3 transaminitis and HLH developing within hours of dose #5 = 90 µg/kg and dose #3 = 60 µg/kg, respectively. Tolerability was no different in minimal residual disease (MRD) vs. high blast burden settings. The study is ongoing, but the maximum tolerated dose post alloSCT is likely 30-60 µg/kg.
Three patients with MRD-only relapses achieved MRD-negative complete remission which, in the longest case (the patient with HLH), has been sustained >8 months. No responses were seen in overt morphological relapse. Responders began DR-18 at median 92 days (71-213) after HCT vs. 15 months (14-54.5) for non-responders.
DR-18 generated robust, on-target immune activation: serum IL-18 and the IFNγ-induced chemokine CXCL9 rose 1-2 logs after dose 1 and dose 4 (both p<0.05; CXCL9 to ~5,000-10,000 pg/mL), confirming engagement of the IFNγ axis. Blood single-cell RNA sequencing demonstrated induction of STAT1/IFNγ signaling and T-cell activation after DR-18 with significantly upregulated IFNγ response genes (STAT1, GBP5, ISG20, MT2A) in CD4 and CD8 memory subsets (p<0.0001). A population of activated NK-like CD8 T cells markedly expanded after dosing and upregulated IFNγ, antigen presentation and cytolytic programs (e.g., STAT1, CD74, numerous HLA class II genes, GZMB, PRF1). Among non-responders, leukemic cells likewise upregulated IFNγ response but did not display increased antigen presentation-related gene expression.
Conclusions: This is the first study of exogenous DR-18 administration for hematological malignancies relapsing after alloSCT, demonstrating systemic immune activation associated with CRS. Anti-leukemic efficacy was seen in patients treated early after alloSCT with low disease burden. This study also provides the first direct evidence that IL-18 can induce HLH, raising caution in chimeric antigen receptor T cell settings where IL-18 armoring may induce irreversible IL-18 dysregulation.
DISCLOSURES
Elizabeth Florence Krakow, MD,CM, MSc: Simcha Therapeutics - Research Funding; Promicell, Inc - Research Funding